Evicenter
MarkdownMedical informationP&T meetings
Imsidolimab

Generalized pustular psoriasis

Last updated
83 sources

Section 6 of 6

References

83 sources

  1. AnaptysBio (2017) (opens in a new tab)
  2. AnaptysBio (2018) (opens in a new tab)
  3. AnaptysBio (2020) (opens in a new tab)
  4. AnaptysBio (2021) (opens in a new tab)
  5. AnaptysBio (2024) (opens in a new tab)
  6. AnaptysBio British Journal of Dermatology publication announcement (2023) (opens in a new tab)
  7. AnaptysBio phase 3 topline results announcement (2023) (opens in a new tab)
  8. ANZCTR ACTRN12617000369325 (opens in a new tab)
  9. ANZCTR NCT05352893 (opens in a new tab)
  10. Armstrong et al. (2024) (opens in a new tab)
  11. Bachelez et al. (2021) (opens in a new tab)
  12. Barker et al. (2025) (opens in a new tab)
  13. Bhutani and Farberg (2024) (opens in a new tab)
  14. Bulai Livideanu et al. (2025) (opens in a new tab)
  15. Burden et al. (2023) (opens in a new tab)
  16. Chen et al. (2024) (opens in a new tab)
  17. Chien et al. (2026) (opens in a new tab)
  18. Choon et al. (2021) (opens in a new tab)
  19. Choon et al. (2023) (opens in a new tab)
  20. Choon et al. (2024a) (opens in a new tab)
  21. Choon et al. (2024b) (opens in a new tab)
  22. Choon et al. (2024c) (opens in a new tab)
  23. ClinicalTrials.gov NCT03619902 (opens in a new tab)
  24. ClinicalTrials.gov NCT03619902 protocol (2019) (opens in a new tab)
  25. ClinicalTrials.gov NCT05352893 (opens in a new tab)
  26. ClinicalTrials.gov NCT05352893 protocol (opens in a new tab)
  27. ClinicalTrials.gov NCT05352893 statistical analysis plan (2022) (opens in a new tab)
  28. ClinicalTrials.gov NCT05366855 (opens in a new tab)
  29. ClinicalTrials.gov NCT05366855 protocol (2022) (opens in a new tab)
  30. ClinicalTrials.gov NCT05366855 statistical analysis plan (2022) (opens in a new tab)
  31. DailyMed SPEVIGO prescribing information (2026) (opens in a new tab)
  32. Frysz et al. (2024) (opens in a new tab)
  33. Fujita et al. (2018) (opens in a new tab)
  34. Gleeson and Mahil (2023) (opens in a new tab)
  35. Gottlieb et al. (2025) (opens in a new tab)
  36. Gudjonsson et al. (2022) (opens in a new tab)
  37. Hagenström et al. (2025) (opens in a new tab)
  38. Hanna et al. (2021) (opens in a new tab)
  39. Kam et al. (2024) (opens in a new tab)
  40. Khanskaya et al. (2018) (opens in a new tab)
  41. Kole et al. (2025) (opens in a new tab)
  42. Lebwohl et al. (2025) (opens in a new tab)
  43. Lin et al. (2026) (opens in a new tab)
  44. Lynde et al. (2025) (opens in a new tab)
  45. Marrakchi et al. (2011) (opens in a new tab)
  46. Miyachi et al. (2022) (opens in a new tab)
  47. Morita et al. (2022) (opens in a new tab)
  48. Morita et al. (2023) (opens in a new tab)
  49. Morita et al. (2026) (opens in a new tab)
  50. National Health Care Institute horizon scan (2026) (opens in a new tab)
  51. Navarini et al. (2017) (opens in a new tab)
  52. NICE (2026) (opens in a new tab)
  53. Noe et al. (2022) (opens in a new tab)
  54. Noe et al. (2025) (opens in a new tab)
  55. Norlin et al. (2024) (opens in a new tab)
  56. Patel et al. (2023) (opens in a new tab)
  57. Puig et al. (2023) (opens in a new tab)
  58. Puig et al. (2024) (opens in a new tab)
  59. Reich et al. (2024) (opens in a new tab)
  60. Seah et al. (2025a) (opens in a new tab)
  61. Seah et al. (2025b) (opens in a new tab)
  62. Smieszek et al. (2025) (opens in a new tab)
  63. Smieszek et al. (2026) (opens in a new tab)
  64. Strober et al. (2026a) (opens in a new tab)
  65. Strober et al. (2026b) (opens in a new tab)
  66. Sugiura et al. (2013) (opens in a new tab)
  67. Tada et al. (2024) (opens in a new tab)
  68. Teitsma et al. (2026) (opens in a new tab)
  69. Vanda Pharmaceuticals BLA acceptance announcement (2026) (opens in a new tab)
  70. Vanda Pharmaceuticals BLA submission announcement (2025) (opens in a new tab)
  71. Vanda Pharmaceuticals earnings call transcript (2026) (opens in a new tab)
  72. Vanda Pharmaceuticals EMA orphan designation opinion announcement (2026) (opens in a new tab)
  73. Vanda Pharmaceuticals European Commission orphan designation announcement (2026) (opens in a new tab)
  74. Vanda Pharmaceuticals Form 10-K (2026) (opens in a new tab)
  75. Vanda Pharmaceuticals Form 8-K (2026) (opens in a new tab)
  76. Vanda Pharmaceuticals Japan orphan drug designation announcement (2026) (opens in a new tab)
  77. Vanda Pharmaceuticals license agreement announcement (2025) (opens in a new tab)
  78. Vanda Pharmaceuticals NEJM Evidence publication announcement (2026) (opens in a new tab)
  79. Vanda Pharmaceuticals second quarter 2026 results announcement (2026) (opens in a new tab)
  80. Viguier et al. (2024) (opens in a new tab)
  81. Viguier et al. (2026) (opens in a new tab)
  82. Warren et al. (2023) (opens in a new tab)
  83. Zema et al. (2022) (opens in a new tab)